A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects

NCT02070510 · Completed

Last updated 2026-05-28

This trial tests how the diabetes medication semaglutide taken by mouth affects the levels of the blood pressure drug lisinopril and the blood thinner warfarin in healthy adults.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) treatment study

Participants 52 people

Who can join Ages 18–75 · all sexes Healthy volunteers accepted.

Timeline Started 2014-02 · est. completion 2014-08

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT02070510 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of the trial is to investigate the influence of oral semaglutide (NNC0113-0217) on the pharmacokinetics of lisinopril and warfarin in healthy subjects.

Treatments tested

semaglutide Drug

For oral administration once daily. Doses of 5 mg and 10 mg, respectively, will be given for 7 days followed by 20 mg administered on days 43-84.
lisinopril Drug

For oral administration. A single dose of 20 mg is administered three times either alone or conconmitantly with a perpetrator compound (days 1, 15 and 71).
warfarin Drug

For oral administration. A single dose of 5 mg is administered three times either alone or conconmitantly with a perpetrator compound (days 8, 22 and 78).
placebo Drug

A single dose of SNAC is administered conconmitantly with victim compounds (days 15 and 22).

Main thing measured	Area under the S-warfarin concentration-time curve
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Healthy
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02070510 ↗